CeliVax Technology
Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases
Original CeliVax Technology
Immunological adjuvant
The immunological adjuvant, α-galactosyl ceramide, binds to CD1d molecule of B cells, NK cells and monocytes and induces the activation of Natural Killer T (NKT) cells.
- α-galactosyl ceramide mediates the interaction between the B cells/NK cells/monocytes and Natural Killer T cells. NKT cells activated by the interaction release various kinds of immune boosting cytokines to activate a broad spectrum of immune responses.
Scroll left and right to read.
